MediciNova, Inc. (NASDAQ: MNOV) – Analyst Coverage Initiated; Report by Broad Street

LA JOLLA, CA / ACCESSWIRE / April 4, 2016 / MediciNova, Inc. (NASDAQ: MNOV) a biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market, recently announced that the medical journal Drug and Alcohol Dependence has published a new article regarding positive findings from a completed Phase 1b clinical trial of MN-166 (ibudilast) in methamphetamine dependence. The article, which was written by Matthew J. Worley, Keith G. Heinzerling, and colleagues at the University of California, Los Angeles (UCLA), reports that MN-166 (ibudilast) was shown to significantly reduce the subjective effects of methamphetamine in subjects diagnosed with methamphetamine dependence. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, “We are very pleased that the detailed results of the first clinical trial evaluating MN-166 in methamphetamine-dependent subjects have been published. Based on the reported positive findings from this study, we continue to work in collaboration with researchers at UCLA on a much larger ongoing Phase 2 clinical study to evaluate MN-166 in methamphetamine-dependent subjects.”

The rally has not slowed down and the company is up 122.54% this year. Will a resistance be reached or another broken, see the full report?

Fot the full detailed research report with analyst comments on MediciNova, Inc. (NASDAQ: MNOV) please follow the link. There is no cost obligation required to view analyst brief: http://broadstreetalerts.com/mnov-analyst/.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis by Robert Borowski. An outsourced research services provider represented by Robert Borowski, provided Broad Street Alerts this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Broad Street Alerts is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Robert Borowski. The subject Company has not compensated Broad Street Alerts or Robert Borowski for the creation or dissemination of this report. Broad Street Alerts is the party responsible for issuing the press release and for hosting the full analyst report on Broad Street Alerts website. Robert Borowski is the author of research report. This information is submitted to increase awareness for the Broad Street Alerts brand to our subscriber base and the investing public.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@broadstreetalerts.com. For any urgent concerns or inquiries, please contact us at admin@broadstreetalerts.com.

NOT FINANCIAL ADVICE

Broad Street Alerts makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Broad Street Alerts is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming Broad Street Alerts has compensated Robert Borowski, up to two hundred fifty dollars for the distribution rights to disseminate analyst report. No liability is accepted by Broad Street Alerts whatsoever for any direct, indirect or consequential loss arising from the use of this document. Broad Street Alerts expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Broad Street Alerts does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Broad Street Alerts

ReleaseID: 438391